Clinical trials
Adverse Drug Event clinical trials
Below are recruiting adverse drug event clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05345821Recruiting
Study of side effects and satisfaction after silicone breast implants
This trial follows women who get their first breast implant surgery or a repeat (primary vs secondary) and records side effects and how satisfied they feel. It aims to better understand safety and satisfaction with smooth-surface silicone implants.
Santo André, São PauloAges 18 years+ - NCT04840355Recruiting
Monitoring safety of sintilimab in Chinese patients
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT03356132Recruiting
Breast implant safety and satisfaction follow-up study
This study looks at side effects and satisfaction after breast implant surgery. It may help by sharing what problems happen most and how satisfied people feel after getting a Silimed® textured or Silimed foam-coated implant.
Niterói, Rio de JaneiroAges 18 years+ - NCT04777357RecruitingPhase 3
Cariprazine for bipolar depression in ages 10 to 17
This Phase 3 study tests whether cariprazine can improve depression symptoms in children and teens with bipolar I disorder, and also tracks side effects. It may help if your depressive episode is ongoing and you meet specific mood and screening score requirements.
Bentonville, ArkansasAges 10–17 - NCT07220460RecruitingPhase 2
Study of an oral drug for bipolar depression
This trial tests an experimental pill (ABB-932) for people with bipolar I or II disorder who are currently in a depressive episode. The goal is to see if the drug is safe and helps improve mood.
Phoenix, ArizonaAges 18–65 - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Phoenix, ArizonaAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chandler, ArizonaAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Birmingham, AlabamaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Denver, ColoradoAges 18 years+ - NCT03989323Recruiting
Register to track cancer immune therapy and side effects
This study sets up a real-world patient database to follow people starting cancer immunotherapy and record immune-related side effects. You may help doctors better understand who gets these side effects and how they change over time.
BronAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT05125302RecruitingPhase 3
Ubrogepant for acute migraine relief in kids and teens
This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.
Huntsville, AlabamaAges 6–17 - NCT05889182RecruitingPhase 3
Testing an oral medicine for moderate to severe hidradenitis
This Phase 3 study tests upadacitinib taken by mouth to reduce hidradenitis suppurativa (HS) symptoms and disease activity, and to track side effects. It is for people who have already tried anti-TNF treatments and still had inadequate response or couldn’t tolerate them.
Birmingham, AlabamaAges 12 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Miami, FloridaAges 18 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+
Hear when a new Adverse Drug Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse drug event?
- Yes. Clin2 currently lists 69 recruiting adverse drug event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse drug event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse drug event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.